Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

amaxa to Co-ordinate Collaboration to Develop High Throughput Devices for Primary Cell Transfection

Published: Monday, July 02, 2007
Last Updated: Monday, July 02, 2007
Bookmark and Share
amaxa receives a €2.75M grant from European Commission to develop devices for use in the study of immunological, neuronal and liver disorders.

amaxa AG has announced that it will co-ordinate a European collaboration of eight partners to develop devices for ultra high-throughput delivery and screening of primary cells, for use in the study of immunological, neuronal and liver disorders.

The collaboration has been granted over €2.75 million in funding from the EC and will use amaxa’s Nucleofector® Technology – a method for the transfection of primary cells.

The 36-month project, named MODEST-EU, is a collaboration between amaxa AG (Germany), Deutsches Rheumaforschungszentrum (Germany), RNAx GmbH (Germany), Protobios Ltd (Estonia), Fotec Forschungs- und Technologietransfer GmbH (Austria), HTP High Tech Plastics AG (Austria), Dominion Pharmakine SL (Spain) and Prevas AB (Sweden).

The devices developed using amaxa’s Nucleofector® Technology will represent the world’s first technology enabling high-throughput screenings in transfected and differentiated primary cells. The project will go on to study the application of this technology in the areas of immunology, neurology and liver disorders.

Dr. Birgit Nelsen-Salz, coordinator of the project, said “amaxa is the only institution worldwide, which has the necessary knowledge and experience to adapt the technical needs of device development to the conditions used for efficient transfection of primary cells and hard-to-transfect cell lines. As co-ordinator of the project we will ensure that the expertise brought by each partner will enable the collaboration to achieve the goal of providing powerful new tools for basic research and drug discovery”.

Each partner will play a significant role in the development of the devices: Prevas will be responsible for the building of the device from proof-of-principle up to prototype; Fotec will develop the production process for micro-plates; HTP will be involved in the prototyping of the 384-well plates.

In addition, the application of nucleofection and cell based assays will be assessed by a team of outstanding experts: DRFZ (cell sorting and multiparameter flow-cytometry), RNAx (RNAi technology), Protobios (nervous system development and transcription regulation network) and Dominion Pharmakine (biomarkers related to site specific development of liver metastasis).

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Amaxa to Host Webinar on the Nucleofection® of Stem Cells
The webinar imparts knowledge about setting up embryonic, mesenchymal, hematopoietic or neural stem cell experiments using Nucleofector® Technology.
Thursday, May 01, 2008
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos